Category: General Biotechnology

Manufacturing is dead. Long live manufacturing!

On the same day that AstraZeneca has announced that it intents to completely outsource all of its drug manufacturing, citing the prevalence of external parties who can do it better and cheaper, Sanofi has announced plans toIf you understand the rules and strategies of <a href=”http;//www.now-blackjack.com” mce_href=”http;//www.now-blackjack.com”>free blackajck online</a> it won’t be difficult for you. […]


Upcoming events

I’ll be attending the Mid-Atlantic Bio in Bethesda in late October. On November 8th I’ll be in Turkey speaking at the Biotechnology for Turkey Conference. I’ll be in Toronto in late November, speaking in the AstraZeneca speaker series at the University of Toronto. If you’re interested in more details or want to meet up, drop […]


Building Biotechnology on Facebook

With the start of a new school year, a new cohort of students are entering biotechnology programs. In order to facilitate those who are using my book, Building Biotechnology, I have set up a networking and information group on facebook. I’m always interested in tracking the outcomes of students in biotechnology programs. If you’re a […]


Drug Patent Expirations in September 2007

Courtesy of DrugPatentWatch.com: Drug Patent Expirations in September 2007*Drugs may be covered by more than one patent Tradename Applicant Generic Name Patent Number Patent Expiration BETAXON Alcon levobetaxolol hydrochloride 4,911,920 SEP 27,2007 BETOPTIC S Alcon betaxolol hydrochloride 4,911,920 SEP 27,2007 CARDIOLITE Bristol Myers Squibb technetium tc-99m sestamibi kit 4,885,100 SEP 11,2007 COGNEX Sciele Pharma Inc […]


Amgen's patents protect Epogen. Again.

Amgen’s got a record of savvy patenting to protect their blockbusters, and they’ve just done it again. A U.S. Federal District Court in Boston has ruled that Roche’s pegylated-erythropoietin infringes one of Amgen’s patents. I’m eager to hear the backstory on this one. Amgen previously prevented Transkaryotic (now owned by Shire) from using a completely […]


Amgen’s patents protect Epogen. Again.

Amgen’s got a record of savvy patenting to protect their blockbusters, and they’ve just done it again. A U.S. Federal District Court in Boston has ruled that Roche’s pegylated-erythropoietin infringes one of Amgen’s patents. I’m eager to hear the backstory on this one. Amgen previously prevented Transkaryotic (now owned by Shire) from using a completely […]


Drug approvals fall. Who’s to blame?

The FDA approved 38 drugs through July this year, down 31 percent from 55 approvals for the same period last year. Who’s to blame? According to Friedman, Billings, Ramsey, the FDA. Why? Vioxx. For details on extra scrutiny being applied by the FDA, see this CNNMoney summary.


Carnival of Biotechnology

Welcome to the second August 2007 edition of Carnival of Biotechnology. International Biotechnology The Times (UK) has a report on the UK biotech sector, calling for consolidation to overcome a lack of capital. The Wall Street Journal has an article on Novartis’ lost patent case in India, where a patent on an improved version of […]


Journal of Commercial Biotechnology

I’ve recently joined the Journal of Commercial Biotechnology as managing editor. Drop me a line if you would like to make a submission. The most recent issue, edited by Neil Henderson, has just been published: Volume 13, Issue 3 Articles When should you fire the founder? PDF William Bains Constructing a processual model of communication […]


Do NOT follow this link or you will be banned from the site!
%d bloggers like this: